Ardelyx Leads The Charge With These 3 Compelling Penny Stocks

Simply Wall St.08-18

Over the last 7 days, the United States market has remained flat, though it is up 20% over the past year and earnings are expected to grow by 17% per annum in the coming years. Penny stocks may be a ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2660431196?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","is_english":true,"pubTime":"2026-08-18 01:05","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2660431196","market":"sg","top_or_hot":-1,"title":"Ardelyx Leads The Charge With These 3 Compelling Penny Stocks","media":"Simply Wall St.","content":"<div>\n<p>Over the last 7 days, the United States market has remained flat, though it is up 20% over the past year and earnings are expected to grow by 17% per annum in the coming years. Penny stocks may be a ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-ardx/ardelyx/news/ardelyx-leads-the-charge-with-these-3-compelling-penny-stock\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Ardelyx Leads The Charge With These 3 Compelling Penny Stocks</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nArdelyx Leads The Charge With These 3 Compelling Penny Stocks\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-08-18 01:05 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-ardx/ardelyx/news/ardelyx-leads-the-charge-with-these-3-compelling-penny-stock><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Over the last 7 days, the United States market has remained flat, though it is up 20% over the past year and earnings are expected to grow by 17% per annum in the coming years. Penny stocks may be a ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-ardx/ardelyx/news/ardelyx-leads-the-charge-with-these-3-compelling-penny-stock\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-ardx/ardelyx/news/ardelyx-leads-the-charge-with-these-3-compelling-penny-stock","article_id":"2660431196","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-ardx/ardelyx/news/ardelyx-leads-the-charge-with-these-3-compelling-penny-stock","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2660431196","pubTimestamp":1786986315,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"Over the last 7 days, the United States market has remained flat, though it is up 20% over the past year and earnings are expected to grow by 17% per annum in the coming years. Penny stocks may be a throwback term, but they continue to offer intriguing opportunities for investors seeking growth at lower price points. When backed by strong financial health and solid fundamentals, these stocks can present unique chances for substantial returns without many of the risks typically associated with...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","HHS":"Harte-Hanks","BRSP":"BrightSpire Capital, Inc.","BK4110":"抵押房地产投资信托","ARDX":"Ardelyx","BK4009":"广告"},"translate_title":"Ardelyx 凭借这 3 只引人注目的细价股领先","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"HHS":1,"ARDX":1.5,"BRSP":1},"content_text":"Over the last 7 days, the United States market has remained flat, though it is up 20% over the past year and earnings are expected to grow by 17% per annum in the coming years. Penny stocks may be a throwback term, but they continue to offer intriguing opportunities for investors seeking growth at lower price points. When backed by strong financial health and solid fundamentals, these stocks can present unique chances for substantial returns without many of the risks typically associated with this segment of the market.Let's review some notable picks from our screened stocks.AdvertisementArdelyx (ARDX)Simply Wall St Financial Health Rating: ★★★★☆☆Overview: Ardelyx, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing medicines for unmet medical needs in the United States and internationally, with a market cap of approximately $1.01 billion.Operations: The company generates $450.89 million from its development and commercialization of biopharmaceutical products segment.Market Cap: $1.01BArdelyx, Inc., with a market cap of US$1.01 billion, is navigating the penny stock landscape by focusing on revenue growth and managing its financial health. Although currently unprofitable, Ardelyx has reduced losses over the past five years and reported second-quarter 2026 revenues of US$120.88 million, up from US$97.66 million the previous year. The company maintains a strong cash position with short-term assets exceeding liabilities and has not significantly diluted shareholders recently. However, insider selling in recent months raises caution while management's relatively short tenure suggests potential challenges in strategic continuity.Jump into the full analysis health report here for a deeper understanding of Ardelyx.Learn about Ardelyx's future growth trajectory here.ARDX Debt to Equity History and Analysis as at Aug 2026Harte Hanks (HHS)Simply Wall St Financial Health Rating: ★★★★★★Overview: Harte Hanks, Inc. is a customer experience company operating in the United States and internationally, with a market cap of $31.90 million.Operations: Harte Hanks does not report specific revenue segments.Market Cap: $31.9MHarte Hanks, Inc., with a market cap of US$31.90 million, has been navigating financial challenges typical in the penny stock realm. The company reported a net loss of US$5 million for Q2 2026, widening from the previous year's loss. Despite its unprofitability and increased volatility, Harte Hanks maintains more cash than total debt and short-term assets exceeding liabilities. Recently announced merger plans with Star Equity Holdings value the company at approximately US$38.4 million in equity, offering shareholders cash or preferred stock options. This strategic move could potentially stabilize operations under Star's Business Services division post-merger completion expected later this year.Take a closer look at Harte Hanks' potential here in our financial health report.Examine Harte Hanks' past performance report to understand how it has performed in prior years.HHS Debt to Equity History and Analysis as at Aug 2026BrightSpire Capital (BRSP)Simply Wall St Financial Health Rating: ★★★★☆☆Overview: BrightSpire Capital, Inc. is a commercial real estate credit REIT operating in the United States and Norway with a market cap of approximately $632.62 million.Operations: The company's revenue is primarily derived from Senior and Mezzanine Loans and Preferred Equity at $199.76 million, followed by Net Leased and Other Real Estate at $129.17 million, with a smaller contribution from Corporate and other activities totaling $6.87 million.Market Cap: $632.62MBrightSpire Capital, Inc., with a market cap of US$632.62 million, faces challenges typical in the penny stock sector. Despite being unprofitable, it has reduced losses over five years and maintains a cash runway exceeding three years thanks to positive free cash flow. The company's dividend yield of 12.8% is not well covered by earnings or free cash flows, raising concerns about its sustainability. BrightSpire's short-term assets surpass both short- and long-term liabilities, but its net debt to equity ratio remains high at 291.7%. Recent inclusion in the Russell 2000 Index could enhance visibility among investors.Get an in-depth perspective on BrightSpire Capital's performance by reading our balance sheet health report here.Examine BrightSpire Capital's earnings growth report to understand how analysts expect it to perform.BRSP Revenue & Expenses Breakdown as at Aug 2026Taking AdvantageTake a closer look at our  US Penny Stocks list of 318 companies by clicking here.Want To Explore Some Alternatives? Trump has pledged to \"unleash\" American oil and gas and these 23 US stocks have developments that are poised to benefit.  This article by Simply Wall St is general in nature. We provide commentary based on historical data \n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your \n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data. \n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. \n    Simply Wall St has no position in any stocks mentioned.Valuation is complex, but we're here to simplify it.Discover if Harte Hanks might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.Access Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":false,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.48.0","shortVersion":"4.48.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2660431196","isCrawlerRequest":true}